Wells Fargo & Company Kiniksa Pharmaceuticals, Ltd. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KNSA
# of Institutions
8Shares Held
1.95MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V81.52MShares$33.4 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$4.46 Million2.82% of portfolio
-
Harbor Capital Advisors, Inc.97.5KShares$2.15 Million0.11% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$870,2710.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$661,2000.69% of portfolio
About Kiniksa Pharmaceuticals, Ltd.
- Ticker KNSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,470,400
- Market Cap $760M
- Description
- Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...